Cruising on the midstage clinical success of a brain cancer therapy, Day One Biopharmaceuticals is using the wind at its sails to bolster the back of its pipeline with a $3 million upfront deal for Sprint Bioscience's preclinical program.
LAFOX, Ill., March 15, 2022 (GLOBE NEWSWIRE) -- Richardson Electronics, Ltd. (NASDAQ: RELL), which is a global provider of engineered solutions for diagnostic imaging equipment, is pleased to...
Sprint Bioscience AB (publ), a company develops small-molecule first-in-class drug projects with a focus on oncology, has licensed its cancer drug programme Vps34 to Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the programme.
STOCKHOLM, Aug. 3, 2021 /PRNewswire/ -- Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million, plus additional tiered percentage royalties ranging from the mid-single-digits to the low-double-digits on the sales of a future drug from the program, if approved. On signing of the agreement, Sprint Bioscience will receive an upfront payment of USD 4 million, which will be entered into the accounts for the third quarter of 2021.
STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- Newly published results from three independent research groups support the concept behind Sprint Biosciences' drug project Vps34. The articles confirm that autophagy in tumors makes it easier for cancer cells to escape attacks from the body's immune system. This external validation leads to an increased interest in the Vps34 project in the pharmaceutical industry and strengthens Sprint Biosciences' position in discussions with potential licensees.